Fontbonne A, Currie A, Tounian P, Picot M-C, Foulatier O, Nedelcu M, et al. Prevalence of overweight and obesity in france: the 2020 Obepi-Roche study by the “Ligue Contre l’Obésité”. J Clin Med. 2023;12:925.
Article PubMed PubMed Central Google Scholar
Lazzati A, Bechet S, Jouma S, Paolino L, Jung C. Revision surgery after sleeve gastrectomy: a nationwide study with 10 years of follow-up. Surg Obes Relat Dis. 2020;16:1497–504.
Brown WA, Liem R, Al-Sabah S, Anvari M, Boza C, Cohenet V, et al. IFSO global registry collaboration. metabolic bariatric surgery across the IFSO chapters: key insights on the baseline patient demographics, procedure types, and mortality from the eighth IFSO global registry report. Obes Surg. 2024;34:1764–77.
Article PubMed PubMed Central Google Scholar
Mann JP, Jakes AD, Hayden JD, Barth J. Systematic review of definitions of failure in revisional bariatric surgery. Obes Surg. 2015;25:571–4.
Nasta AM, Goel R, Singhal R, Lemmens L, Baig S, Seki Y, et al. 30-day morbidity and mortality of revisional bariatric surgery - An international multi-centre collaborative (BROAD) study. Obes Res Clin Pract. 2024;18:195–200.
Moulis G, Lapeyre-Mestre M, Palmaro A, Pugnet G, Montastruc J-L, Sailler L. French health insurance databases: what interest for medical research? Revue Med Interne. 2015;36:411–7.
Tuppin P, de Roquefeuil L, Weill A, Ricordeau P, Merlière Y. French national health insurance information system and the permanent beneficiaries sample. Rev Épidémiol Santé Publique. 2010;58:286–90.
Article CAS PubMed Google Scholar
Bousquet C, Souvignet J, Merabti T, Sadou E, Trombert B, Rodrigues J-M. Method for mapping the French CCAM terminology to the UMLS metathesaurus. Stud Health Technol Inform. 2012;180:164–8.
Charlson ME, Carrozzino D, Guidi J, Patierno C. Charlson comorbidity index: a critical review of clinimetric properties. Psychother Psychosom. 2022;91:8–35.
Clapp B, Wynn M, Martyn C, Foster C, O’Dell M, Tyroch A. Longterm (7 or more years) outcomes of the sleeve gastrectomy: ameta-analysis. Surg Obes Relat Dis. 2018;14:741–7.
Felsenreich DM, Ladinig LM, Beckerhinn P, Sperker C, Schwameis K, Krebs M, et al. Update:10 years of sleeve gastrectomy—The first 103 patients. ObesSurg. 2018;28:3586–94.
Mahawar KK, Graham Y, Carr WRJ, Jennings N, Schroeder N, Balupuriet S, et al. Revisional Roux-en-Y gastric bypass and sleeve gastrectomy: a systematic review of comparative outcomes with respective primary procedures. Obes Surg. 2015;25:1271–80.
Axer S, Szabo E, Agerskov S, Näslund I. Predictive factors of complications in revisional gastric bypass surgery: results from the Scandinavian obesity surgery registry. Surg Obes Relat Dis Off J Am Soc Bariatr Surg. 2019;15:2094–100.
El Chaar M, Stoltzfus J, Melitics M, Claros L, Zeido A. 30-day outcomes of revisional bariatric stapling procedures: first report based on MBSAQIP data registry. Obes Surg. 2018;28:2233–40.
Pedziwiatr M, Malczak P, Wierdak M, Rubinkiewicz M, Pisarska M, Major P, et al. Revisional gastric bypass is inferior to primary gastric bypass in terms of short-and long-term outcomes-systematic review and meta-analysis. Obes Surg. 2018;28:2083–91.
Article PubMed PubMed Central Google Scholar
Salman M, Salman M, Elewa A, Elsherbiny M, Tourkey M, Chikukuza S, et al. Outcomes of revisional surgery options after inadequate sleeve gastrectomy: a comprehensive network meta-analysis. World J Surg. 2024;48:2040–57.
Spurzem GJ, Broderick RC, Kunkel EK, Hollandsworth H, Sandler B, Jacobsen G, et al. Robotic bariatric surgery reduces morbidity for revisional gastric bypass when compared to laparoscopic: outcome of 8-year MBSAQIP analysis of over 40,000 cases. Surg Endosc. 2024;38:6294–304.
Article PubMed PubMed Central Google Scholar
Redmond IP, Shukla AP, Aronne LJ. Use of weight loss medications in patients after bariatric surgery. Curr Obes Rep. 2021;10:81–9.
Miras AD, Pérez-Pevida B, Aldhwayan M, Kamocka A, McGlone E, Al-Najim W, et al. Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7:549–59.
Comments (0)